Holen Sie sich die Stockscreener-App
15.43
5.79%
0.835
Eton Pharmaceuticals Inc Aktie (ETON) Neueste Nachrichten
What analysts say about Eton Pharmaceuticals Inc. stockLightning-fast capital gains - jammulinksnews.com
Eton Pharmaceuticals Inc. Stock Analysis and ForecastBreakthrough financial growth - jammulinksnews.com
Is Eton Pharmaceuticals Inc. a good long term investmentRapid return acceleration - jammulinksnews.com
What drives Eton Pharmaceuticals Inc. stock priceExtraordinary profit generation - jammulinksnews.com
What makes Eton Pharmaceuticals Inc. stock price move sharplyHigh Yield Opportunities - Newser
Top Growth Companies With Insider Stakes July 2025 - simplywall.st
B. Riley Analysts Lift Earnings Estimates for ETON - Defense World
B. Riley Boosts Earnings Estimates for Eton Pharmaceuticals - Defense World
ETON’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
How Eton Pharmaceuticals Inc. stock performs during market volatilityLow Risk Profit Ideas - Newser
Why Eton Pharmaceuticals Inc. stock attracts strong analyst attentionCapital Preservation Investment Ideas - Newser
Eton Pharmaceuticals: A Contrarian Play on Delayed Catalysts and Long-Term Value - AInvest
Eton Pharma Near Term Catalysts Vanish (NASDAQ:ETON) - Seeking Alpha
(ETON) Trading Report - news.stocktradersdaily.com
Institutional investors are Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) biggest bettors and were rewarded after last week's US$48m market cap gain - simplywall.st
FDA accepts Eton’s NDA for ET-600 desmopressin oral solution By Investing.com - Investing.com South Africa
Eton Pharmaceuticals Announces Fda Acceptance of New Drug Application for Et-600 (Desmopressin Oral Solution) - MarketScreener
Eton stock gains as new therapy gets FDA review (ETON) - Seeking Alpha
Eton Pharmaceuticals announces FDA acceptance of new drug application for ET-600 - MarketScreener
FDA accepts Eton’s NDA for ET-600 desmopressin oral solution - Investing.com
Eton Pharmaceuticals Announces FDA Acceptance of NDA for ET-600 with Target Action Date of February 25, 2026 - Quiver Quantitative
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution) - The Manila Times
Eton's New Pediatric Drug Solution Advances Toward FDA Approval, Targeting $1B Market Opportunity - Stock Titan
Eton Pharmaceuticals to join Russell indexes - MSN
Eton Pharmaceuticals (ETON) to Join Russell 3000 and 2000 Indexes | ETON Stock News - GuruFocus
Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes - The Manila Times
ETON switches auditor: Crowe LLP out, Grant Thornton in – no disputes | ETON SEC FilingForm 8-K - Stock Titan
Opaleye Management Inc. Increases Stake in Eton Pharmaceuticals Inc. - GuruFocus
Insiders Back These 3 High Growth Companies - Yahoo Finance
Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) 25% Cheaper Price Remains In Tune With Revenues - simplywall.st
Bank of America Corp DE Boosts Stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
Insider Sell: David Krempa Sells 34,000 Shares of Eton Pharmaceu - GuruFocus
Insider Sell: David Krempa Sells 34,000 Shares of Eton Pharmaceuticals Inc (ETON) - GuruFocus
Eton Pharma wins FDA nod for oral hydrocortisone solution - MSN
Eton Pharmaceuticals, Inc. (ETON) Launches Game-Changer for Adrenal Insufficiency - MSN
Major Shareholder Increases Stake in Eton Pharmaceuticals! - TipRanks
Eton Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Trend Tracker for (ETON) - news.stocktradersdaily.com
B. Riley Forecasts Higher Earnings for Eton Pharmaceuticals - Defense World
Eton Pharmaceuticals: Rapid Revenue Growth And Pipeline Catalysts Point To More Upside - Seeking Alpha
Insider Sell: Sean Brynjelsen Sells 210,000 Shares of Eton Pharm - GuruFocus
1.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):